Previous Article | Next Article 
Molecular and Cellular Biology, January 2003, p. 607-619, Vol. 23, No. 2
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.2.607-619.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
The inv(16) Fusion Protein Associates with Corepressors via a Smooth Muscle Myosin Heavy-Chain Domain
Kristie L. Durst,1 Bart Lutterbach,1,
Tanawan Kummalue,2 Alan D. Friedman,2 and Scott W. Hiebert1,3*
Department of Biochemistry,1
Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232,3
Department of Oncology, Johns Hopkins University, Baltimore, Maryland 212312
Received 22 April 2002/
Returned for modification 6 June 2002/
Accepted 14 October 2002
Inversion(16) is one of the most frequent chromosomal translocations found in acute myeloid leukemia (AML), occurring in over 8% of AML cases. This translocation results in a protein product that fuses the first 165 amino acids of core binding factor ß to the coiled-coil region of a smooth muscle myosin heavy chain (CBFß/SMMHC). CBFß interacts with AML1 to form a heterodimer that binds DNA; this interaction increases the affinity of AML1 for DNA. The CBFß/SMMHC fusion protein cooperates with AML1 to repress the transcription of AML1-regulated genes. We show that CBFß/SMMHC contains a repression domain in the C-terminal 163 amino acids of the SMMHC region that is required for inv(16)-mediated transcriptional repression. This minimal repression domain is sufficient for the association of CBFß/SMMHC with the mSin3A corepressor. In addition, the inv(16) fusion protein specifically associates with histone deacetylase 8 (HDAC8). inv(16)-mediated repression is sensitive to HDAC inhibitors. We propose a model whereby the inv(16) fusion protein associates with AML1 to convert AML1 into a constitutive transcriptional repressor.
* Corresponding author. Mailing address: Department of Biochemistry, Vanderbilt University School of Medicine, PRB 512, 23rd and Pierce, Nashville, TN 37232. Phone: (615) 936-3582. Fax: (615) 936-1790. E-mail: scott.hiebert{at}mcmail.vanderbilt.edu.
Present address: Merck, Inc., West Point, Pa.
Molecular and Cellular Biology, January 2003, p. 607-619, Vol. 23, No. 2
0022-538X/03/$08.00+0 DOI: 10.1128/MCB.23.2.607-619.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Cheng, C. K., Li, L., Cheng, S. H., Lau, K. M., Chan, N. P. H., Wong, R. S. M., Shing, M. M. K., Li, C. K., Ng, M. H. L.
(2008). Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia. Blood
112: 3391-3402
[Abstract]
[Full Text]
-
Hoemme, C., Peerzada, A., Behre, G., Wang, Y., McClelland, M., Nieselt, K., Zschunke, M., Disselhoff, C., Agrawal, S., Isken, F., Tidow, N., Berdel, W. E., Serve, H., Muller-Tidow, C.
(2008). Chromatin modifications induced by PML-RAR{alpha} repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood
111: 2887-2895
[Abstract]
[Full Text]
-
Kim, H.-G., Kojima, K., Swindle, C. S., Cotta, C. V., Huo, Y., Reddy, V., Klug, C. A.
(2008). FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. Blood
111: 1567-1574
[Abstract]
[Full Text]
-
Markus, J., Garin, M. T., Bies, J., Galili, N., Raza, A., Thirman, M. J., Le Beau, M. M., Rowley, J. D., Liu, P. P., Wolff, L.
(2007). Methylation-Independent Silencing of the Tumor Suppressor INK4b (p15) by CBF{beta}-SMMHC in Acute Myelogenous Leukemia with inv(16). Cancer Res.
67: 992-1000
[Abstract]
[Full Text]
-
Lee, H., Sengupta, N., Villagra, A., Rezai-Zadeh, N., Seto, E.
(2006). Histone Deacetylase 8 Safeguards the Human Ever-Shorter Telomeres 1B (hEST1B) Protein from Ubiquitin-Mediated Degradation.. Mol. Cell. Biol.
26: 5259-5269
[Abstract]
[Full Text]
-
Moreno-Miralles, I., Pan, L., Keates-Baleeiro, J., Durst-Goodwin, K., Yang, C., Kim, H.-G., Thompson, M. A., Klug, C. A., Cleveland, J. L., Hiebert, S. W.
(2005). The inv(16) Cooperates with ARF Haploinsufficiency to Induce Acute Myeloid Leukemia. J. Biol. Chem.
280: 40097-40103
[Abstract]
[Full Text]
-
Frohling, S., Scholl, C., Gilliland, D. G., Levine, R. L.
(2005). Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications. JCO
23: 6285-6295
[Abstract]
[Full Text]
-
Yang, G., Khalaf, W., van de Locht, L., Jansen, J. H., Gao, M., Thompson, M. A., van der Reijden, B. A., Gutmann, D. H., Delwel, R., Clapp, D. W., Hiebert, S. W.
(2005). Transcriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein. Mol. Cell. Biol.
25: 5869-5879
[Abstract]
[Full Text]
-
Ito, K., Ito, M., Elliott, W. M., Cosio, B., Caramori, G., Kon, O. M., Barczyk, A., Hayashi, S., Adcock, I. M., Hogg, J. C., Barnes, P. J.
(2005). Decreased Histone Deacetylase Activity in Chronic Obstructive Pulmonary Disease. NEJM
352: 1967-1976
[Abstract]
[Full Text]
-
Zhang, X., Ozawa, Y., Lee, H., Wen, Y.-D., Tan, T.-H., Wadzinski, B. E., Seto, E.
(2005). Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev.
19: 827-839
[Abstract]
[Full Text]
-
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., Steinkuhler, C., Di Marco, S.
(2004). Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA
101: 15064-15069
[Abstract]
[Full Text]
-
Schroeder, T. M., Kahler, R. A., Li, X., Westendorf, J. J.
(2004). Histone Deacetylase 3 Interacts with Runx2 to Repress the Osteocalcin Promoter and Regulate Osteoblast Differentiation. J. Biol. Chem.
279: 41998-42007
[Abstract]
[Full Text]
-
So, C. W., Cleary, M. L.
(2004). Dimerization: a versatile switch for oncogenesis. Blood
104: 919-922
[Abstract]
[Full Text]
-
Waltregny, D., de Leval, L., Glenisson, W., Ly Tran, S., North, B. J., Bellahcene, A., Weidle, U., Verdin, E., Castronovo, V.
(2004). Expression of Histone Deacetylase 8, a Class I Histone Deacetylase, Is Restricted to Cells Showing Smooth Muscle Differentiation in Normal Human Tissues. Am. J. Pathol.
165: 553-564
[Abstract]
[Full Text]
-
Huang, G., Shigesada, K., Wee, H.-J., Liu, P. P., Osato, M., Ito, Y.
(2004). Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood
103: 3200-3207
[Abstract]
[Full Text]
-
Lee, H., Rezai-Zadeh, N., Seto, E.
(2004). Negative Regulation of Histone Deacetylase 8 Activity by Cyclic AMP-Dependent Protein Kinase A. Mol. Cell. Biol.
24: 765-773
[Abstract]
[Full Text]
-
Krauter, J., Gorlich, K., Ottmann, O., Lubbert, M., Dohner, H., Heit, W., Kanz, L., Ganser, A., Heil, G.
(2003). Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor Leukemias. JCO
21: 4413-4422
[Abstract]
[Full Text]
-
Zhang, L., Li, Z., Yan, J., Pradhan, P., Corpora, T., Cheney, M. D., Bravo, J., Warren, A. J., Bushweller, J. H., Speck, N. A.
(2003). Mutagenesis of the Runt Domain Defines Two Energetic Hot Spots for Heterodimerization with the Core Binding Factor {beta} Subunit. J. Biol. Chem.
278: 33097-33104
[Abstract]
[Full Text]
Copyright © 2003 by the American Society for Microbiology. All rights reserved.